Finasteride Tablet, Film Coated
Product Images NDC 70518-3616

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 70518-3616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Finasteride is a medication available in the form of 5 mg tablets with 30 pills per bottle. It is manufactured by Aurohindo located in Nagar, India. The medication comes with a warning stating that it is not suitable for women or children, and women who could potentially become pregnant. The directions for use can be found in the package insert. The medication should be stored in a cool and dry place, away from children. It has been repackaged by RemedyRepack Inc in Indiana.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

This appears to be a chart showing the mean change from baseline in symptom score for two long-term efficacy and safety studies using placebo and finasteride. The chart displays data for a period of 4 years (baseline, year 1, year 2, year 3, and year 4). The numbers listed under "Finasteride" indicate the mean change from baseline for each year of the study. It is not possible to determine the unit of measurement or the specific condition being studied without more context.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

This appears to be a figure displaying the percentage of patients who had surgery for BPH (benign prostatic hyperplasia) while taking either finasteride or a placebo over an observation time of up to 48 months. The graph shows that the percentage of patients who underwent surgery was lower in the finasteride group compared to the placebo group. The numbers of events and patients at risk are also shown for each group.*

FDA Label Image

Figure3 (Finasteride Fig3)

FDA Label Image

Figure4 (Finasteride Fig4)

This text shows a chart (Figure 4) presenting the Mean Percent Change from Baseline + 1 SE in Prostate Volume in a Long-Term Efficacy and Safety Study. The chart shows the baseline, year 1, year 2, year 3, and year d results for a placebo group (n=155) and a Finasteride group (n=157). The results indicate a decrease in prostate volume over the years for both groups.*

FDA Label Image

Figure5 (Finasteride Fig5)

FDA Label Image

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.